Merck reports Phase 2 CADENCE data for WINREVAIR in CpcPH-HFpEF
Merck reported Phase 2 CADENCE results showing WINREVAIR met the primary endpoint in adults with CpcPH-HFpEF. The company said the data support advancement into a registrational Phase 3 study.